Deal-making between big pharma and biotech looks set to rise with a looming patent cliff increasing the need for the former to replenish its pipelines. Meanwhile, biotechs need partners to help them advance amid the ongoing big freeze on raising cash on public markets.

Venture capital and private equity firms pumped a combined $102m into seven Chinese biotechs in major deals announced during December.

Average R&D spending by the top 25 biopharma companies increased as a percent of sales from 14.4% in 2010 to 17% in 2020, according to an EY report.

Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.